Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Abstract Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I hist...

Full description

Bibliographic Details
Main Authors: Stephen G. Smoots, Anna R. Schreiber, Marilyn M. Jackson, Stacey M. Bagby, Adrian T A. Dominguez, Evan D. Dus, Cameron A. Binns, Morgan MacBeth, Phaedra A. Whitty, Jennifer R. Diamond, Todd M. Pitts
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Breast Cancer Research
Subjects:
Triple-negative breast cancer
Doxorubicin
Histone deacetylase inhibitor
Online Access:https://doi.org/10.1186/s13058-024-01799-5

Internet

https://doi.org/10.1186/s13058-024-01799-5

Similar Items